CD274 and lung cancer: Immune check point inhibitors (ICIs), comprising of monoclonal antibodies against programmed cell death protein-1 (PD-1) such as nivolumab, pembrolizumab and programmed death-ligand1 (PD-L1) such as atezolimumab and durvalumab, have been reported to improve the clinical response in few subsets of lung cancer patients.